1-6 of 6
Hilary Coye
Close
Sort by
Journal Articles

Concurrent pembrolizumab with AVD for untreated classic Hodgkin lymphoma

Clinical Trials & Observations
Ryan C. Lynch, Chaitra S. Ujjani, Christina Poh, Edus H. Warren, Stephen D. Smith, Mazyar Shadman, Brian Till, Vikram M. Raghunathan, Stefan Alig, Ash A. Alizadeh, Avanti Gulhane, Delphine L. Chen, Yolanda Tseng, Hilary Coye, Megan Shelby, Susan Ottemiller, Sarith Keo, Kaitlin Verni, Hongyan Du, Jacquelin Vandermeer, Ashley Gaston, Heather Rasmussen, Paul Martin, Edmond Marzbani, Jenna Voutsinas, Ajay K. Gopal
Journal: Blood
Blood (2023) 141 (21): 2576–2586.
https://doi.org/10.1182/blood.2022019254
Published: 2023
Includes: Supplemental data
Journal Articles

Circulating Tumor DNA in Untreated Classical Hodgkin Lymphoma Patients Treated with Pembrolizumab and Chemotherapy: Dynamic Response Assessment and Correlation with Baseline Metabolic Tumor Volume

Ryan C. Lynch, Stefan K. Alig, Chaitra S. Ujjani, Christina Poh, Edus H. Warren, Stephen D. Smith, Mazyar Shadman, Andrei Shustov, Brian G. Till, Vikram Raghunathan, Yolanda D. Tseng, Hilary Coye, Megan Shelby, Susan Ottemiller, Sarith Keo, Kaitlin Verni, Hongyan Du, Jacquelin Vandermeer, Ashley Gaston, Heather A. Rasmussen, Avanti Gulhane, Delphine Chen, Eric Wayne Dean, Paul S. Martin, Edmond A Marzbani, Jenna M. Voutsinas, Ash A. Alizadeh, Ajay K. Gopal
Journal: Blood
Blood (2022) 140 (Supplement 1): 6547–6549.
https://doi.org/10.1182/blood-2022-160234
Published: 2022
Journal Articles

Concurrent Pembrolizumab with AVD for Untreated Classical Hodgkin Lymphoma

Ryan C. Lynch, Chaitra S. Ujjani, Christina Poh, Edus H. Warren, Stephen D. Smith, Mazyar Shadman, Andrei R Shustov, Brian G. Till, Yolanda D. Tseng, Hilary Coye, Megan Shelby, Susan Ottemiller, Hongyan Du, Jacquelin Vandermeer, Heather A. Rasmussen, Stefan Alig, Ash A. Alizadeh, Avanti Gulhane, Delphine Chen, Eric Wayne Dean, Jason Lukas, Paul S. Martin, Edmond A Marzbani, Jenna Voutsinas, Ajay K Gopal
Journal: Blood
Blood (2021) 138 (Supplement 1): 233.
https://doi.org/10.1182/blood-2021-144610
Published: 2021
Journal Articles

Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma

Chaitra S. Ujjani, MD, Catherine Lai, MD MPH, Lori A. Leslie, MD, Pari Ramzi, RN, Ming Tan, Siyu Wang, Hongkun Wang, Eunice Shim, Nicole Swanson, Catherine M Broome, Ajay K. Gopal, MD, Stephen D. Smith, MD, Edus H. Warren, MD PhD, Katie Blue, Sabrina Kdiry, BSN, Brian G. Till, MD, Ryan C. Lynch, MD, Mazyar Shadman, MD MPH, Michael Johnson, Hilary Coye, PA-C, Megan Shelby, PA-C, Yolanda D. Tseng, MD, Andrei Shustov, MD, David G. Maloney, MD PhD, Bruce D. Cheson, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 46–47.
https://doi.org/10.1182/blood-2020-136219
Published: 2020
Journal Articles

Dose-Dense Brentuximab Vedotin Plus Ifosfamide, Carboplatin, and Etoposide (ICE) Is Highly Active for Second Line Treatment in Relapsed/Refractory Classical Hodgkin Lymphoma: Final Results of a Phase I/II Study

Ryan C. Lynch, MD, Ryan D. Cassaday, MD, Stephen D. Smith, MD, Jonathan R. Fromm, MD PhD, Andrew J. Cowan, MD, Edus H. Warren, MD PhD, Mazyar Shadman, MDMPH, Andrei R Shustov, MD, Brian G. Till, MD, Chaitra S. Ujjani, MD, Edward Libby, MD, Mary Philip, MDPhD, Hilary Coye, PA-C, Christen N. Martino, NP, Sandra Kanan, MSN, ARNP, Karolyn K. Morris, BA, Heather A. Rasmussen, BS, Sanaz Behnia, MD, Margaret E. Nartea, BS, Jenna M. Voutsinas, MPH, Ajay K. Gopal, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 16–18.
https://doi.org/10.1182/blood-2020-133763
Published: 2020
Journal Articles

A Pilot Trial of Adriamycin, Pembrolizumab, Vinblastine and Dacarbazine (APVD) for Patients with Untreated Classical Hodgkin Lymphoma

Ryan C. Lynch, MD, Chaitra S. Ujjani, MD, Edus H. Warren, MD PhD, David M. Kurtz, MD PhD, Hilary Coye, PA-C, Jacquelin Vandermeer, BS, Hongyan Du, MD, Adam Greenbaum, MD PhD, Ajay K. Gopal, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 5299.
https://doi.org/10.1182/blood-2019-124997
Published: 2019